Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on developing innovative red cell therapeutics (RCTs) to combat severe diseases. Its pipeline features RTX-240 and RTX-224, both advancing as treatments for solid tumor cancers, alongside RTX-aAPC for various other oncological conditions. The company is also progressing RTX-321 for HPV-positive tumors and RTX-T1D for the management of type 1 diabetes.